Philip Cornford

Jan 10, 2025 | sciencedirect.com | Sara Tyebally |Avirup Guha |Derya Tilki |Philip Cornford

© 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Dec 24, 2024 | europeanurology.com | Matthew J. Roberts |Philip Cornford |Derya Tilki

Get full text accessLog in, subscribe or purchase for full access. ReferencesTouijer, K.A. ∙ Sjoberg, D.D. ∙ Benfante, N. ... Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trialEur Urol Oncol. 2021; 4:532-539Lestingi, J.F.P. ∙ Guglielmetti, G.B. ∙ Trinh, Q.D. ...

Sep 25, 2024 | europeanurology.com | Ivo G. Schoots |Philip Cornford

Get full text accessLog in, subscribe or purchase for full access. ReferencesNewcomb, L.F. ∙ Schenk, J.M. ∙ Zheng, Y. ... Long-term outcomes in patients using protocol-directed active surveillance for prostate cancerJAMA. 2024; 331:2084-20932. Kasivisvanathan, V. ∙ Rannikko, A.S. ∙ Borghi, M. ... MRI-targeted or standard biopsy for prostate-cancer diagnosisN Engl J Med. 2018; 378:1767-17773. Weinstein, I.C. ∙ Wu, X. ∙ Hill, A. ...

May 22, 2024 | europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more

Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.